BioSpace News Archive

Arcutis Biotherapeutics, Inc. announced the closing of its initial public offering of 10,781,250 shares of its common stock at a price to the public of $17.00 per share, which includes 1,406,250 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.

NuVasive, Inc. announced the Company will release its fourth quarter and full year 2019 earnings results on Thursday, February 20, 2020 after the close of the market.

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 8% in the company’s quarterly cash dividend, beginning in the first quarter of 2020

TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), today announced data from a non-human primate study demonstrating favorable response to reinforced biologic material used in a hernia repair compared to seven clinically used biologic and synthetic products.

Total revenues were $5.6 billion during the fourth quarter of 2019, compared with $5.1 billion in the fourth quarter of 2018.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2019. Total revenues for the fourth quarter of 2019 were $5.9 billion compared to $5.8 billion for the same period in 2018.

Sage Therapeutics, Inc. announced that on Monday, February 3, 2020, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 13,950 shares of its common stock, and 6,325 performance restricted stock units to four new employees under Sage’s 2016 Inducement Equity Plan.

Legends for Charity has raised nearly $8 million in 15 years for the lifesaving mission of St. Jude Children’s Research Hospital®.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock.